Hyqvia Reduces Relapse in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Trial

Hyqvia reduced relapses in patients with chronic inflammatory demyelinating polyradiculoneuropathy, according to phase 3 data.

Related Keywords

Kristina Allikmets ,Head Of Research Development For Takeda Plasma ,Inflammatory Neuropathy Cause ,Plasma Derived Therapies Business ,